Alistair Irvine | Chief Executive Officer
Scarlet Therapeutics

Alistair Irvine, PhD, joined Scarlet as Founding CEO in August 2022. He is an experienced biotech and medtech executive who has worked in the industry for >30 years and has broad international executive and R&D experience. Previous to Scarlet, he was Chief Business Officer at Kuros Biosciences AG, a company which now has a market cap around $1B. He has also held senior management roles at Innovata plc, ML Laboratories plc, and Cobra Therapeutics Ltd. Dr. Irvine holds a PhD in Molecular Biology from the University of Sheffield, U.K. and a BSc in biochemistry from the University of Edinburgh, U.K. He is a British citizen.

Appearances:

Day 1 - Tuesday 28 October @ 13:00

Start-ups Pitches

13:00: Dr Mona Boyé, CBDO, Ksilink: Automation and high throughput phenotypic screening of patient-based cellular systems for novel treatment options for rare diseases

13:05: Dr Boris Sevarika, Co-Founder & CEO, NanoZymeX: Overcoming Limitations of Current Enzyme Replacement Therapies

13:10: Dr William Jang, Head of Global BD, BioMe

13:15: Dr Sumira Riaz, Founder & Health Psychologist, Unboxed Psychology: Applications of behaviour science: Introducing Unboxed Psychology

13:20: Leonid Stoianov, CEO, Trialize

13:25: Julian Howell, M.D., Founder & CEO, PharmaKrysto: Cystinuria – new approaches to preventing cystine stones – moving to clinical development

13:30: Fabrice Lejeune, CSO, Genvade Therapeutics: Overcoming the Nonsense in Genetic Diseases

13:35: Dr Alistair Irvine, CEO, Scarlet Therapeutics

13:40: Flaminia Macchia, COO, ORPHANET-AISBL

13:45: Vincent Leveque, Co-Founder & CEO, Mirava Bio: Breaking Barriers: Bringing Rare Disease Therapies to Patients in Europe

Mona Boyé, CBO, Ksilink

Sumira Riaz, Founder, Health Psychologist & Patient Engagement Consultant, Unboxed Psychology